Acorda's $525m Civitas buy: Sign of Parkinson's deal surge?
This article was originally published in Scrip
Executive Summary
Civitas Therapeutics has a lot to offer its buyer Acorda Therapeutics, including global diversification and an inhaled drug platform technology. The private company's $525m acquisition adds to a growing list of recent transactions in the Parkinson's disease field.
You may also be interested in...
Acorda Investor Scopia Seeks Big Return From Sale Of The Company
Citing recent deals, hedge fund Scopia encouraged Acorda's board on Aug. 7 to pursue a sale, but the company believes its new strategy focused on Parkinson's disease is best for shareholders.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.